This study aimed to evaluate the impact of the secondary cytoreductive surgery on survival parameters in women with platinum-sensitive recurrent ovarian cancer who undergone secondary cytoreduction following chemotherapy compared to women who recieved chemotherapy alone.
In a retrospective study, data were rewieved from women who were diagnosed and treated with ovarian cancer and its primary platinum-sensitive recurrence at the University Hospital Brno in the Czech Republic between November 2009 and March 2016. Out of the total number of 62 patients with recurrence, 30 women underwent cytoreductive surgery plus chemotherapy and 32 were treated with chemotherapy alone. The good performance status expressed by ECOG score 0–1, the single site of recurrence regardless of platinum-free interval or multiple sites of recurrence but no carcinomatosis and platinum-free interval >12 months, and no or small-volume ascites (<500 ml) were considered inclusion criteria for cytoreductive surgery. Women not meeting these criteria were treated by chemotherapy alone. Descriptive statistics, Kaplan-Meier survival curves and Log-Rank test were used for statistical estimations.
The analysis confirmed more favorable prognosis in patient group treated with a combination secondary cytoreduction and chemotherapy. Mean disease-free survival (DFS) was 49.8 months (95% CI; 33.2–66.3) and mean overall survival (OS) stood at 54.0 months (95% CI; 39.4–68.6) in this patient cohort, while in patient group treated with chemotherapy alone it was found that mean DFS was 16.6 months (95% CI; 7.4–25.8) and mean OS stood at 26.2 months (95% CI; 16.6–35.8). When testing the difference between survival curves, statistically significant differences were observed in both DFS (p = 0.010) and OS (p = 0.007) rates between two treatment groups. Age < 60 years at the time of recurrence and zero macroscopic residual disease after secondary cytoreduction were identified as favorable prognostic factors for both DFS and OS in a multivariate analysis.
Secondary cytoreductive surgery is acceptable as a viable treatment option for highly selected women with ovarian cancer recurrence. Complete resection is considered ultimate goal of secondary cytoreduction on condition that the balance between maximal survival gain and minimal operative morbidity will be kept.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Obstetrics and Gynecology and Reproductive Biology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Howlader N. Noone A.M. Krapcho M. SEER cancer statistics review, 1975–2012. National Cancer Institute, Bethesda, MD2015 (based on November 2014 SEER data submission, posted to the SEER web site, April 2015 (accessed March 15, 2018))
- 2012 v1.0, cancer incidence and mortality worldwide: IARC cancerBase No. 11 [internet].(Available from:) International Agency for Research on Cancer, Lyon, France2013 (accessed March 15, 2018)
- Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.Gynecol Oncol. 2015; 139: 10-16
- Surgical cytoreduction for recurrent epithelial ovarian cancer.Cochrane Database Syst Rev. 2013; 28CD008765
- Surgery for relapsed ovarian cancer: when should it be offered?.Curr Oncol Rep. 2012; 14: 539-543
- Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 40 consecutive patients.J Surg Oncol. 2010; 102: 656-662
- Surgical management of recurrent ovarian cancer.Gynecol Oncol. 2016; 142: 357-367
- Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer.Eur J Surg Oncol. 2010; 36: 583-588
- Prognostic significance of sugarbaker’s peritoneal cancer index for the operability of ovarian carcinoma.Int J Gynecol Cancer. 2015; 25: 135-144
- The clavien-dindo classification of surgical complications: five-year experience.Ann Surg. 2009; 250: 187-196
- Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.Cancer. 2006; 106: 1933-1939
- Arbeitsgemeinschaft gynaekologische onkologie ovarian committee; AGO ovarian cancer study group. Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial.Ann Surg Oncol. 2006; 13: 1702-1710
- Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO.Int J Gynecol Cancer. 2011; 21: 289-295
- Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer.Gynecol Oncol. 2014; 132: 537-541
- Secondary complete cytoreduction in recurrent ovarian cancer: benefit of optimal patient selection using scoring system.Int J Gynecol Cancer. 2014; 24: 238-246
- External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer.Gynecol Oncol. 2015; 137: 210-215
- A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.Ann Surg Oncol. 2012; 19: 597-604
- A predictive score for secondary cytoreductive surgery in recurrent ovarian cancer (SeC-score): a single-centre, controlled study for preoperative patient selection.Ann Surg Oncol. 2015; 22: 4217-4223
- Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.Int J Clin Oncol. 2016; 21: 573-579
- Quality of life in platinum-sensitive recurrent ovarian cancer: chemotherapy versus surgery plus chemotherapy.Ann Surg Oncol. 2015; 22: 2387-2394
- CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery.J Ovarian Res. 2013; 11: 14-20
- Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?.Gynecol Oncol. 2010; 117: 336-340
- CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer.Gynecol Oncol. 2011; 121: 249-252
- Predictive value of PET–CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer.Eur J Obstet Gynecol Reprod Biol. 2008; 140: 263-268
- Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up.Ann Oncol. 2011; 22: 40-44
- [(18)F]FDG PET/MRI vs. PET/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results.Eur J Nucl Med Mol Imaging. 2015; 42: 56-65
- Systematic review on the accuracy of positron emission tomography/computed tomography and positron emission tomography/magnetic resonance imaging in the management of ovarian cancer: Is functional information really needed?.World J Nucl Med. 2017; 16: 176-185
Published online: June 20, 2018
Accepted: June 14, 2018
Received: March 29, 2018
© 2018 Elsevier B.V. All rights reserved.